· Livatag® Phase III trial in HCC: 50% of patients randomized
  · Scientific recognition of Validive® and Beleodaq® preclinical and clinical
data at ASCO Annual Meeting and MASCC/ISOO International Symposium
  · Sound financial position with €42.9 million cash
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, today reported its consolidated half-year accounts as of June 30, 2015
and provided an update on the key operational and clinical milestones achieved
during the first six months of the year.

“The first half year of 2015 has been extremely active for Onxeo. We have
continued the Phase III clinical trial of Livatag® to reach 50% of our patient
recruitment target while preparing the opening of new countries, in regions with
a high prevalence of hepatocellular carcinoma (HCC). In parallel, Onxeo has been
particularly active focusing on elevated scientific exchange, with an increased
visibility at several key medical congresses devoted to oncology, including two
posters presented at theAmerican Society of Clinical Oncology (ASCO) Annual
Meeting (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fam.asco
. 
org%2F&esheet=51153316&newsitemid=0&lan=en
-US&anchor=American+Society+of+Clinical+Oncology+%28ASCO%29+Annual+Meeting&index
= 
1&md5=4b07440eb5b3286a790d7a0bdcbe1d9f). The second half of 2015 will also be
significant for the company’s development. We are preparing to initiate a
Validive® Phase III trial in severe oral mucositis (SOM) in patients with head
and neck cancer receiving chemoradiation therapy. We also plan to share the
Phase I safety results of Beleodaq® in combination with chemotherapy (BelCHOP)
in 1st line treatment of peripheral T-cell lymphoma (PTCL), which are expected
at the end of the year. This step is required to finalize the preparatory work
on the Beleodaq® Phase III study protocol. We strongly believe that our
achievements over this first semester contribute to strengthening our unique
pipeline and further positioning Onxeo as a leading player in this attractive
market,” commented Judith Greciet, CEO of Onxeo.

Key events of the first half 2015

Livatag®: Progression of “ReLive” Phase III trial

  · 50% of the 400 patients randomized; more than 100 patients treated with
Livatag® totaling approximately 450 infusions in the trial to date; this
recruitment rate is in line with expected timelines of issuing preliminary
outcomes of the Phase III by 1H 2017.
  · Trial expansion into 4 new countries, Lebanon, Egypt, the Kingdom of Saudi
Arabia and Turkey, to boost patient recruitment; study now authorized in a total
of 11 countries.
Positive assessment of the 6th Data Safety Monitoring Board (DSMB) in April
confirmed Livatag®’s excellent safety profile. The next DSMB is planned for
October.

Validive®: Phase III preparation following positive Phase II trial

  · Final Phase II data presented at 2015 ASCO Annual Meeting and 2015
MASCC/ISOO International Symposium on Supportive Care in Cancer.
  · Positive efficacy and safety profiles confirmed in prevention of severe oral
mucositis in patients with head and neck cancer.
  · Phase III trial to be initiated in 1H 2016.

Beleodaq®: Phase I safety data of Beleodaq® combination with chemotherapy
(BelCHOP) expected by year-end 2015

  · Pivotal Phase II BELIEF (PXD101-CLN-19) trial data published in June in
the Journal of Clinical Oncology, showing positive results as monotherapy,
including complete and durable responses, in treating rare cancer PTCL in
2nd line.
  · Phase I results and safety profile of Beleodaq® + CHOP combination expected
4Q 2015, which will allow for the finalization of the Phase III protocol in
treatment of PTCL in 1st line.
  · Preclinical and clinical results from three studies supporting the potential
of Beleodaq® in multiple orphan oncology indications, including results from its
Phase I/II trial of Beleodaq® in combination with standard chemotherapy in
patients with soft tissue sarcomas (STS), were presented at the 2015 ASCO Annual
Meeting.

New International partnerships on Sitavig® and Loramyc®

Sitavig®

In July 2015, Onxeo signed a license agreement for Sitavig® (acyclovir Lauriad®)
with specialty pharmaceutical company Bruno Farmaceutici for commercialization
in Italy. Sitavig® is approved for the treatment of recurrent labial herpes in
Europe and in the U.S. As a partner, Bruno Farmaceutici will launch Labiriad®
(name of Sitavig® in Italy) under its current regulatory status (prescription)
and manage the regulatory procedure to obtain an over-the-counter (OTC)
designation, allowing pharmacists to deliver Sitavig® to patients directly.

Loramyc®/Oravig®

In March 2015, Onxeo signed a licensing agreement with Dara BioSciences, a
company specializing in oncology support care, giving exclusive rights to
commercialize Oravig® in the U.S. and in Canada. Oravig® is planned for launch
by the Dara BioSciences commercial team in the U.S. in 4Q 2015, and Onxeo will
receive sales-related milestones. Dara BioSciences should be acquired by UK
-based Midatech, which will strengthen its financial resources and broader
organizational capabilities.

Collaborative program

Fluriad™

The Fluriad™ program initiated in 2011 was aiming at establishing proof of
concept for the use of the Lauriad® mucoadhesive tablet for vaccination purpose.
This collaborative program was supported by a “Fond Unique Interministériel”
(“FUI”) grant.

Onxeo will not pursue the program further considering that the Fluriad™ program
is not in line with Onxeo’s core strategy in the orphan oncology space. However,
the company has entered into discussions with certain of the consortium partners
on an agreement allowing them to continue the program development, against
compensation to Onxeo in event of success.

1H 2015 consolidated accounts

Consolidated          30/06/2015(        30/06/2014(        30/06/2014
accounts (IFRS        6 months)          6 months)          pro forma
-compliant)In
thousands
Euros
Revenues              1,533              653                13,872
Incl.                 1,219              268                268
recurring
revenues
Incl. non             314                384                13,604
recurring
revenues
Operating             (13,502)           (9,188)            (11,475)
expenses
Incl. R&D             (7,832)            (5,662)            (7,188)
expenses
Operating             (11,969)           (8,535)            2,397
profit/loss
Non-recurring         0                  (4,397)            (9,270)
charges linked
to the merger
Financial             832                24                 73
income
Income tax            (200)              0                  (873)
Net                   (11,347)           (12,951)           (7,659)
profit/loss


According to IFRS, the above 2014 figures do not take into account the activity
of Topotarget as the merger of this entity into BioAlliance Pharma, creating
Onxeo, was effective on June 30, 2014. In order to ensure full comparability
between 2015 and 2014, a pro forma P&L account is presented as if the merger had
taken place on January 1, 2014. It takes into account all revenues and expenses
of Topotarget over 1H 2014 that were not included in the consolidated 1H results
in application of IFRS.

Recurring revenues increased significantly compared to 2014 as a result of the
U.S. commercialization of Beleodaq® by partner Spectrum Pharmaceuticals and
Sitavig® by Innocutis/Cipher in 3Q 2014.

In the absence of any contractual milestone during the period, non-recurring
revenues are limited to the revenue recognition of upfront payments received in
previous years as per IAS 18 (as a reminder, a $10m milestone relating to FDA
approval for filing of Beleodaq® had been received from Spectrum Pharmaceuticals
in 1H 2014 and was booked as revenues in the pro forma accounts).

Operating expenses were impacted by an increase in R&D expenses essentially as a
result of the deployment of Livatag® international Phase III and its
industrialization program, which is in line with the planned use of proceeds
announced during the Company’s most recent capital increase. While remaining
under a tight control, other operating expenses have increased, as a result of
the new dimension of the company and of new activities in support of the company
growth strategy.

Financial income increased significantly compared to 2014 due to positive
exchange rate differences.

Consolidated cash position at the end of June totaled 42.9 million Euros,
compared to 49.5 million Euros end of March, confirming the healthy situation of
the company and the good long term visibility.

The full half-year financial report (regulated information) is available
on www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%
2 
Fwww.onxeo.com&esheet=51153316&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=2&md5=fadf3423834ba0dd0d48e7338134fd2c) in the
sections “Financial information” and “Regulated information” of the page
“Investors”. The 2015 half-year financial results were subject to a review by
the Company’s Statutory Auditors.

Onxeo will comment on major current issues and its semester financial statements
during its SFAF meeting which will be held on September 16, 2015 at 11:30am at
the Intercontinental Paris Avenue Marceau (64, avenue Marceau – 75015 Paris) and
during the audio/web conference the same day at 5:30 pm:

Tel: +33 (0)1 70 77 09 35
Webconference: https://www.anywhereconference.com/?UserAudioMode=DATA&Name=&Conf
e 
rence=135295222&PIN=635192 (http://cts.businesswire.com/ct/CT?id=smartlink&url=h
t 
tps%3A%2F%2Fwww.anywhereconference.com%2F%3FUserAudioMode%3DDATA%26Name%3D%26Con
f 
erence%3D135295222%26PIN%3D635192&esheet=51153316&newsitemid=0&lan=en
-US&anchor=https%3A%2F%2Fwww.anywhereconference.com%2F%3FUserAudioMode%3DDATA%26
N 
ame%3D%26Conference%3D135295222%26PIN%3D635192&index=3&md5=6b072a56065361a1e0359
6 
53caf9915a)
Audio Playback Numbers : +33(0)1 72 00 15 00
Audio Playback Reference : 295222#

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results
Beleodaq® (belinostat): registered in the US in 2nd line treatmentof peripheral
T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51153316&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=472f593bd1e0df48b56990058c3d02af)

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51153316&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=5&md5=e59a8b167
6 
570ad7c056ddfd4906b53a)
Follow us on twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51153316&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=6&md5=d205ee79cfd01669844979200f8a82d3)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51153316&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=7&md5=87edba55ba7064a4dc11d72356136a83)).
Contacts

Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 47 38 90 04